



Biotech Daily

Friday March 30, 2012

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH DOWN: CELLMID UP 15%, SUNSHINE HEART DOWN 6%**
- * **HEARTWARE BUYS WORLDHEART FOR \$8m**
- * **NUSEP BORROWS \$300k TO EXPAND CONSUMMABLES BUSINESS**
- * **OPTISCAN TAKES \$2m BERGEN DRAW-DOWN EQUITY FACILITY**
- * **AVITA HOLDS ROME SKIN CONFERENCE**

MARKET REPORT

The Australian stock market slipped a further 0.06 percent on Friday March 30, 2012, with the S&P ASX 200 down 2.7 points to 4,335.2 points.

Nine of the Biotech Daily Top 40 stocks were up, nineteen fell, five traded unchanged and seven were untraded.

Cellmid was the best, up 0.2 cents or 15.4 percent to 1.5 cents with 9.6 million shares traded.

Antisense climbed 5.9 percent; Impedimed and Phylogica were up more than four percent; Psivida rose 2.1 percent; Cochlear, Resmed, Tissue Therapies and Universal Biosensors were up more than one percent; with Biota and Heartware up by less than one percent.

Sunshine Heart led the falls, down 0.2 cents or 5.6 percent to 3.4 cents with 600,000 shares traded.

Nanosonics and Neuren fell four percent or more; Allied Health, Genetic Technologies, Pharmaxis, Prana and Viralytics lost more than three percent; Bionomics, Circadian, Clinuvel, Phosphagenics and Reva shed two percent or more; CSL, Mesoblast, QRX and Starpharma were down more than one percent; with Acrux, Alchemia and Sirtex down by less than one percent.

HEARTWARE INTERNATIONAL

Heartware says it will acquire Worldheart for US\$8 million (\$A7.7 million), to be paid in shares of common stock or cash, at Heartware's election.

Heartware chief executive officer Doug Godshall said that the Salt Lake City, Utah-based Worldheart "has been an important participant in the development of ventricular assist therapies for many years and has amassed over 100 patents and patent applications". "In line with our goal to be a leader in the [ventricular assist device] market for years to come, we believe that bolstering our patent portfolio and adding Worldheart's technologies broadens our options for the future," Mr Godshall said.

Heartware said the takeover would see each share of Worldheart common stock either being converted into the right to receive a quota of shares of Heartware common stock or cash equal to the per share merger consideration.

The company said that consideration would be determined by dividing \$US8 million by the number of shares of Worldheart common stock outstanding on a fully diluted basis about 29 US cents per share at today's fully diluted World Heart common stock outstanding.

Heartware said the boards of directors of both companies had approved the transaction, which was subject to Worldheart stockholder approval and other customary closing conditions, but Heartware stockholder approval was not required.

The company said that certain Worldheart stockholders had entered into voting agreements with Heartware to vote a certain number of their shares of Worldheart common stock in favor of the merger at the Worldheart stockholders' meeting.

Heartware said the takeover was expected to close in about 90 days and Worldheart's operations will be integrated into those of Heartware.

Heartware was up one cent or 0.6 percent to \$1.81 with 12 shares traded.

OPTISCAN

Optiscan has a \$2 million draw-down equity facility from Bergen Global Opportunity Fund managed by New York's Bergen Asset Management, formerly related to Springtree Special Opportunities Fund.

Optiscan said that the facility underpinned its balance sheet, allowing progress of its confocal microscope systems with Zeiss.

The company said that in mid March 2012, three category 1 current procedural terminology (CPT) codes were approved regarding the use of optical endomicroscopy in the gastrointestinal tract, with those codes scheduled for implementation in January 2013.

Optiscan said the codes were significant "and underscores the acceptance of the technology and its benefits since Optiscan and Pentax launched the world's first endomicroscope, the Pentax ISC-1000 in 2006".

Optiscan said that Bergen would invest in a \$220,000 24-month interest-free convertible security on execution of the agreement, and investments in \$165,000 to \$900,000 24-month interest-free convertible securities would be made quarterly with a minimum of \$165,000 once a quarter, which could be increased to up to \$900,000 by mutual consent, over the course of a total of eight quarters.

The company said that each convertible security would be purchased at a price equal to 90 percent of its face value and the total amount invested by Bergen would not exceed \$2,000,000 and that Bergen would receive a commencement fee of 877,192 shares.

Optiscan was untraded at 13.5 cents.

[NUSEP](#)

Nusep says it has arranged a \$300,000 working capital advance to accelerate the expansion of its consumables business.

Nusep said that the fully-drawn working capital facility had been provided on normal commercial terms.

The company said the interest rate was eight percent per annum and the due for payment on June 24, 2012.

Nusep said the loan facility was secured over the assets of the company and would be provided by parties related to director Andrew Goodall.

Nusep was untraded at 2.2 cents.

[AVITA MEDICAL](#)

Avita says it sponsored the inaugural Skin Regeneration Symposium held in Rome, Italy, March 23 and 24, 2012.

Avita said the two day event provided an opportunity for users of Recell spray-on skin to present their clinical research and experience in skin regeneration.

The company said that a multi-disciplinary group of 24 Recell experts met with company leaders to advise on clinical best practices, clinical trials and product enhancement.

Avita said that an open session on March 24, was attended by more than 120 clinicians and physicians from 13 countries throughout Europe and the Middle East.

The company said that panel discussions covered the application of Recell in burn treatment, plastic and aesthetic applications, including the treatment of scar and vitiligo, and facial rejuvenation and hard-to-heal wounds, including treatment of venous and diabetic foot ulcers and other chronic/challenging wounds.

Avita said that expert panels provided Recell information and training "to a large and influential network of surgeons and clinicians seeking the best therapies for treating wounds and skin defects".

Avita chief executive officer Dr William Dolphin said that regenerative medicine was "fundamentally changing the way we think about the treatment of a wide range of diseases, injuries and tissue defects".

"Recell, as one of the first regenerative therapeutic technologies available, provides a new and tremendously powerful tool for surgeons and is markedly resetting their expectation for patient outcomes," Dr Dolphin said.

Avita was unchanged at 24 cents.

Last night Avita's new Nasdaq code of AVMXV was unchanged at \$US5.00 with 357 shares traded, but the previous code of AVMXF was up half a US cent or 1.96 percent to 26 US cents, with 46,463 shares traded.